ALENDRONATE SODIUM IN OSTEOARTHRITIS: EFFECTS ON ANABOLIC, CARTILAGE DEGREDATIVE MARKERS AND THE CLINICAL ACTIVITY.

  • Ass. Prof. in Pharmacology Department. College of Medicine, University of Al-Qadisiyah.Iraq.
  • Ass. Prof in Pharmacology Department. College of Medicine, University of Baghdad.Iraq.
  • Professor. College of Medicine, University of Baghdad.Iraq.
Crossref Cited-by Linking logo

  • Abstract
  • References
  • Cite This Article as
  • Corresponding Author

Objective: Osteoarthritis (OA) is a common arthritic disorder and responsible for 2 % of disability in all world. OA affects all joint parts including cartilage, bone and synovium which characterized by degradation of cartilage, subchondral bone turn over and osteophytes formation. Aim of the study:To evaluate the effect of alendronate sodium (ALN) on disease activity and physical function, evaluate the biochemical parameters that are related to OA patients and study the impact of ALN on bone anabolic and degradative marker, and to determine its effectiveness in slowing progression of disease. Patients and methods:116 OA patients over 45 years old with Kellgren and Lawrence X-ray grade II and more were enrolled in this study. Base line assessment was done, Kellgren and Lawrence X-ray grading, WOMAC scoring, body mass index and the biochemical parameters with enzyme-linked immunosorbent assay (ELISA) analysis of serum TGF (transforming growth factor) beta 1 and C-terminal cross linked -telopeptide of type II collagen (CTXII. They were instructed to take ALN 10 mg daily. Reassessment was done after 3 months. Results :Asignificant symptomatic improvement in WOMAC scoring regarding pain and stiffness were observed associated with significant reduction in serum CTXII, TGF beta 1. A no significant reduction in serum calcium with no significant changes in serum Alkaline phosphatase C-reactive protein function and joint space width were also reported. Conclusion: ALN in patients with OA has clinical efficacy in reducing symptoms especially pain probably through inhibition of TGF beta 1 with no significant structural improvement despite reduction of CTXII , and may help delay and prevent further disease progression probably through inhibition of TGF ?1 activity in the subchondral bone.

  1. Alejandro M. IL1 and its role in osteoarthritis. OpenJournal of medicine Vol 1, No 1 (2011).
  2. Alshami A. Knee osteoarthritis related pain: a narrative review of diagnosis and treatment. Int J Health Sci (Qassim). 2014 Jan; 8(1): 85–104.
  3. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage. 2013, 21: 16-21.
  4. Bertoldo F., Pancheri S., Zenari S., et al. Serum 25-Hydroxyvitamin D Levels Modulate the Acute-Phase Response Associated With the First Nitrogen-Containing Bisphosphonate Infusion. Journal of Bone and Mineral Research 2010; 25 (3): 447–454.
  5. Blagojevic M, Jinks C, Jeffery Aet al. Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis. Osteoarthritis Cartilage. 2010, 18: 24-33.
  6. Bobyn J, Thompson R, Lim L, et al. Local alendronic acid elution increases net periimplant bone formation: a micro-CT analysis. Clin Orthop Relat Res.2014 Feb;472(2):687-94.
  7. Brandt K, Mankin H, Shulman L. Workshop on etiopathogenesis of osteoarthritis, J Rheumatol 1986,13, 1126-1160.
  8. Carbone L, Nevitt M, Wildy K, et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 2004; 50(11): 3516-3525.Ceciliani F, Giordano A, Spagnolo V. The systemic reaction during inflammation: the acute-phase proteins. Protein Pept Lett. 2002; 9: 211–223.
  9. Clifton O, Chris J, Patrick G, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: Results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis and Rheumatology Volume 54, Issue 11November 2006 Pages 3494–3507.
  10. Cryer B and Bauer D. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?Mayo Clin Proc. 2002 Oct;77(10):1031-43.
  11. Dam E, Byrjalsen I, Karsdal M et al. Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarthritis and Cartilage Volume 17, Issue 3, March 2009, Pages 384–389.
  12. Esser S and Bailey A. Effects of exercise and physical activity on knee OA. Curr Pain Headache Rep.2011;15:423–30.
  13. Evans K,  Lau S,  Oberbauer A,et al. Alendronate affects long bone length and growth plate morphology in the oimmouse model for Osteogenesis Imperfecta.BoneVolume 32, Issue 3, March 2003, Pages 268–274.
  14. Evio S. Hormone therapy in elderly women; a comparative study with alendronate of the effects on bone, cardiovascular risk factors, periodontal conditions and quality of life. Academic dissertation; Department of Obstetrics and Gynecology, and Division of Endocrinology, Department of Medicine, Helsinki University Central Hospital University of Helsinki, Finland. (2006) Pp 49.
  15. Fernandes J, Martel-Pelletier J, Pelletier J. The role of cytokines in osteoarthritis pathophysiology. Biorheology. 2002;39(1-2):237-46.
  16. Frank H, Anne-Marie L, Shuting S, et al. The relationship between the chemistry and biological activity of the bisphosphonatesBoneVolume 49, Issue 1, July 2011, Pages 20–33.
  17. Fujita T, Fujii Y, Okada SF, Miyauchi A, Takagi Y. Analgesic effect of etidronate on degenerative joint disease. J Bone Miner Metab 2001; 19: 251–256.
  18. Galluzzo S, Santini D, Vincenzi B, et al. Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity. Expert Opin Ther Targets 2007; 11: 941–954.
  19. Gehua Z, Xu C. TGF? signaling in subchondral bone and articular cartilage homeostasis. Trends in Pharmacological sciences Volume 35, Issue 5, May 2014, Pages 227–236.
  20. Gehua Z,  Chunyi W,  Xiaofeng J,  et al. Crane. Inhibition of TGF–? signaling in subchondral bone mesenchymal stem cells attenuates osteoarthritis. Nat Med. 2013 Jun; 19(6): 704–712.
  21. He D, Yin M, Luo Y, Wei Q. Research progress of protective effects of alendronate on articular cartilage in osteoarthritis. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2012 Oct;26(10):1187-90.
  22. Heckbert S, Li G, Cummings S, Smith N, et al.. Use of Alendronate and Risk of Incident Atrial Fibrillation in Women. Arch Intern Med. 2008; 168 (8): 826-831.
  23. Horikawa A., Miyakoshi N., Shimada Y., et al. A comparative study between intravenous and oral alendronate administration for the treatment of osteoporosis. Springer Plus 2015; 4:675-679.
  24. Hunter D. Advanced imaging in osteoarthritis.Bull NYU Hosp Jt Dis. 2008. 66(3):251-60.
  25. Hu H, Zhang L, Li B, et al. In vitro effect of alendronate on chondrocytes and articular cartilage and subchondral bone in rabbit anterior cruciate ligament transection model. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2009 Dec;23(12):1474-81.Í?eri O,  ?ener G,  Yüksel M. Ghrelin against alendronate-induced gastric damage in rats J Endocrinol December 1 2005 187399-406.
  26. Jia J, Yao W, Amugongo S, et al. Prolonged alendronate treatment prevents the decline in serum TGF-?1 levels and reduces cortical bone strength in long-term estrogen deficiency rat model. Bone 2013; 52: 424–432.Jinks C, Jordan K, Croft P. Measuring the population impact of knee pain and disability with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Pain 2002; 100: 55–64.
  27. Jokar M, Mirfeizi Z, Keyvanpajoh K. The Effect of Alendronate on Symptoms of Knee Osteoarthritis: A Randomized Controlled Trial. Iranian Journal of Medical Sciences IJMS (2010) Vol 35, No 1:9-15. Jorge A, Santos C, Raquel L, et al. Osteoarthritis associated with estrogen deficiency. Arthritis Res Ther. 2009; 11(5): 241. Karsdal M , Bay-Jensen A , Lories R, et al. The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments? : Ann Rheum Dis2014;73:336-348.
  28. Keefe F, Lefebvre J, Egert J, et al. The relationship of gender to pain, pain behavior, and disability in osteoarthritis patients: the role of catastrophizing.2000 Sep;87(3):325-34.
  29. Kellgren J, Lawrence J. Radiological assessment of osteoarthrosis. Ann Rheum Dis. 1957;16:494–502.
  30. Khosla S, Burr D, Cauley J, et al.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.American Society for Bone and Mineral Research J Bone Miner Res. 2007 Oct; 22(10):1479-91.
  31. Kress B. Bone alkaline phosphatase: methods of quantitation and clinical utility. J Clin Ligand Assay. 1998; 21(2):139–148.
  32. Lenart A, Lorich G , Lane M. Atypical Fractures of the Femoral Diaphysis in Postmenopausal Women Taking AlendronateN Engl J Med 2008; 358(12):1304-1306.
  33. Lewis R. knee osteoarthritis: Acetaminophen least Effective Choice in Medscape. Jan 07,2015.
  34. Lin Bisphosphonates: A review of their pharmacokinetic properties.Bone Volume 18, Issue 2, February 1996, Pages 75-85.
  35. Link T, Steinbach L, Ghosh S, et al. Osteoarthritis: MR imaging findings in different stages of disease and correlation with clinical findings. Radiology 2003; 226: 373–81.
  36. Mahjoub M, Berenbaum F, Houard X. Why subchondral bone in osteoarthritis? The importance of the cartilage bone interface in osteoarthritis. Osteoporos Int. 2012 ;23(Suppl 8):841–846.
  37. McConnell S, Kolopack P and Davis AM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties. Arthritis Rheum 2001; 45:453–61.
  38. Michael J, Julie C, Fraser P, et al. Biochemical and molecular mechanisms of action of bisphosphonates. BoneVolum 49, Issue 1, July 2011, Pages 34–41.
  39. Miguel A, Salvador A, Tomas D, et al. Effects of Aminobisphosphonates and Thiazides in Patients With Osteopenia/Osteoporosis, Hypercalciuria, and Recurring Renal Calcium LithiasisUrologyVolume 81, Issue 4, April 2013, Pages 731–737.Mohan G, Perilli E, Parkinson I. et al. Pre-emptive, early, and delayed alendronate treatment in a rat model of knee osteoarthritis: effect on subchondral trabecular bone microarchitecture and cartilage degradation of the tibia, bone/cartilage turnover, and joint discomfort. Osteoarthritis Cartilage. 2013 Oct;21(10):1595-604.
  40. Naniwa T, Maeda T, Mizoshita T, et al. Alendronate-induced esophagitis: possible pathogenic role of hypersensitivity to alendronate. Intern Med. 2008;47(23):2083-5. Epub 2008 Dec 1.
  41. Neogi M, Ensrud K, Bauer D, et al. The effect of alendronate on progression of spinal osteophytes and disc-space narrowing. Ann Rheum Dis2008;67:1427-1430.
  42. Nijs R, Jacobs J, Lems W, et al. Alendronate or Alfacalcidol in Glucocorticoid-Induced Osteoporosis N Engl J Med 2006; 355:675-684August 17, 2006.
  43. Nishii T, Tamura S, Shiomi T, et al. Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial.Clin Rheumatol (2013); 32(12): pp. 1759–1766.
  44. Patricia A, Tina L, Jesse A, et al. Pain, Disability, and Depression in Osteoarthritis: Effects of Race and Sex J Aging HealthJune 21, 2011.
  45. Radin E andRose R. Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop 1986; 213: 34–40.
  46. Reid I  and  Hosking D. Bisphosphonates in Paget's disease. BoneVolume 49, Issue 1, July 2011, Pages 89–94.
  47. Richard E, Jennifer S, Nelson B, et al. Bisphosphonates for postmenopausal osteoporosis. BoneVolume 49, Issue 1, July 2011, Pages 82–88.
  48. Rogers M. New insights into the molecular mechanisms of action of bisphosphonates.Curr Pharm Des2003;9:2643-2658
  49. Rossini M, Adami S, Fracassi E, et al. Effects of intra-articular clodronate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial Rheumatol Int, 35 (2015), pp. 255–263.
  50. Saviola G and Santoro L. Clodronate in erosive osteoarthrosis of the hand: efficacy for pain and function recovery. G Ital Med Lav Ergon 2000; 22: 328–331.
  51. Scanzello C and Goldring S.The role of synovitis in osteoarthritis pathogenesis. 2012 Aug; 51(2):249-57.
  52. Sharma L. Osteoarthritis year in review 2015: clinical. OA and cartilage January 2016Volume 24, Issue 1, Pages 36–48
  53. Siebelt M, Waarsing J, Groen H, et al. Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression. 2014 Sep; 66:163-70.
  54. Spector T, Conaghan P, Buckland-Wright J, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial. Arthritis Res Ther 2005; 7: R625-33.
  55. Suri S and Walsh D. Osteochondral alterations in osteoarthritis. Bone. 2012;51(2):204–211.
  56. Tadashi H, Maureen P, Gregg A, et al. The role of subchondral bone remodeling in osteoarthritis: Reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis & Rheumatology Volume 50, Issue 4April 2004 Pages 1193–1206.
  57. Van der Kraan P, Blaney Davidson E, van den Berg W. A role for age-related changes in TGFbeta signaling in aberrant chondrocyte differentiation and osteoarthritis. Arthritis Res Ther. 2010;12(1):201.
  58. Van der P. Age-related alterations in TGF beta signaling as a causal factor of cartilage degeneration in osteoarthritis. Biomed Mater Eng. 2014;24(1 Suppl):75-80.
  59. Vijaykumar M, Gabriel B, Alison M, et al. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis and Rheumatology Volume 60, Issue 7July 2009 Pages 2008–2018.
  60. Voelker R. Few adults with knee osteoarthritis meet national guidelines for physical activity. JAMA.2011;306:1428–30.
  61. Wang Z, Wang W, Zhang L, et al . Effect of alendronate on interleukin-1beta induced chondrocytes of rat in vitro. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2011 Jan;25(1):50-5.
  62. Waikakul S, Sintuvanich N, Assanasuwan T, et al. Efficacy, Side Effects, Safety and Effects on Bone Turnover Markers of once a Week Sandoz Alendronate Sodium Trihydrate 70 mg. Malaysian Orthopaedic Journal 2011 Vol 5 No 2: 15-19.
  63. Willem E, Bakker K, Floris P. Associations of CTX-II with biochemical markers of bone turnover raise questions on its tissue origin: data from CHECK, a cohort study of early osteoarthritis. Ann Rheum Dis2013;72:29-
  64. Yamada Y. Association of a Leu(10)?Pro polymorphism of the transforming growth factor-beta1 with genetic susceptibility to osteoporosis and spinal osteoarthritis. Mech Ageing Dev. 2000;116:113–123.
  65. Yamada Y, Okuizumi H, Miyauchi A, et al. Association of transforming growth factor beta 1 genotype with spinal osteophytosis in Japanese women. Arthritis Rheum.2000;43:452–460. Alendronic Acid 70mg Tablets Last Updated on eMC 05-Feb-2016 View changes.Drug.comZhen G, Wen C, Jia X, et al. Inhibition of TGF–? signaling in subchondral bone mesenchymal stem cells attenuates osteoarthritis. Nature medicine. 2013;19(6):704-A.

[Sinaa Abdul Amir Kadhim, Haidar Mahdi Jawad and Sami Salman Shihab. (2017); ALENDRONATE SODIUM IN OSTEOARTHRITIS: EFFECTS ON ANABOLIC, CARTILAGE DEGREDATIVE MARKERS AND THE CLINICAL ACTIVITY. Int. J. of Adv. Res. 5 (Jan). 2653-2664] (ISSN 2320-5407). www.journalijar.com

Sinaa Abdul Amir Kadhim
Ass. Prof. in Pharmacology Department. College of Medicine

DOI:

Article DOI: 10.21474/IJAR01/3057      
DOI URL: https://dx.doi.org/10.21474/IJAR01/3057

Download Full Paper

Download PDF No. of Downloads: 17 | No. of Views: 149